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Purpose: The late post-illumination pupillary response (PIPR10–30s  ) to blue light is reduced 
in glaucoma, suggesting that pupillometry can be used in clinical glaucoma evaluation. 
Since animal studies have indicated that common anti-glaucomatous agents affect the iris 
muscle, we investigated the short-term effect of the anti-glaucoma drugs on the pupillary 
light reflex and in particular on the PIPR10–30s.
Methods: In this randomized, double-masked, crossover trial, pupillometry was performed 
before and after topical administration of latanoprost, dorzolamide, and timolol in 20 healthy 
subjects. Stimulus was blue (463 nm) and red light (633 nm) of 2 log (lux). Main outcome 
was the PIPR10–30s to blue light. Additionally, pupil size, maximal contraction, and the early 
post-illumination pupillary response (PIPR0–10s   ) to blue and red light were investigated. 
Pupil response variations between 8 a.m. and 2 p.m. were also assessed. Intraocular 
pressure (IOP) was measured before and 3.5 h after drug instillation.
results: We found no drug effect on the blue light PIPR10–30s or any other blue light 
pupil parameters. During the control day, the only significant variation over time was 
observed for the red light PIPR0–10s (p = 0.02). Pupillary size decreased slightly with timolol 
(0.1 mm, p = 0.03) and dorzolamide (0.2 mm, p < 0.001), but not with latanoprost. Timolol 
also reduced the maximal contraction amplitude significantly during red light (p = 0.02). 
Intraocular pressure was significantly reduced by all three drugs after 3.5 h (p < 0.01), 
while it remained unchanged during the control day (p = 0.3).
conclusion: Anti-glaucoma medications did not interfere with the blue light elicited 
PIPR. Dorzolamide reduced pupil size, while timolol reduced both pupil size and maximal 
contraction to red light, but the effect was minute and not of clinical importance.
Keywords: melanopsin, glaucoma, pupillometry, pupillary light reflex, latanoprost, timolol, dorzolamide, iris
introduction
Chromatic pupillometry is a relatively novel research tool for the evaluation of outer and inner retina 
function. The outer retina photoreceptors (rod and cones) exhibit fast temporal kinetics and cause a 
brisk pupillary constriction in response to light, while the inner retinal melanopsin containing intrinsic 
photosensitive retinal ganglion cells (ipRGCs) exhibit slower temporal kinetics and elicit a sustained 
pupillary constriction to light stimuli, persisting after light cessation (1). The melanopsin elicited sustained 
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pupillary response after light offset is termed post-illumination 
pupillary response (PIPR) (2). Three studies, using chromatic pupil-
lometry, have shown decreased pupillary response and in particular 
reduced PIPR in glaucoma patients, indicating functional impair-
ment of the ipRGCs (3–5). Thus, pupillometry may be applied as 
a quick, non-invasive, and objective method to evaluate glaucoma 
progression. However, the pupillary light response is affected by vari-
ous physiological and environmental factors – importantly, topical 
anti-glaucoma drugs may alter this response.
Animal studies have shown that latanoprost and other ocular 
hypotensive prostaglandin analogs such as travoprost, prostaglan-
din F2α, and bimatoprost have different affinities to FP-, E2-, and 
D2-prostaglandin receptor subtypes (6–10). These prostaglandin 
receptors cause contraction in cat and bovine iris sphincter muscle 
(6, 9, 10). Dinslage et al. found that latanoprost decreases constriction 
latency and pupil size in glaucomatous human eyes (11). Pindolol, a 
non-selective beta-blocker used as an anti-glaucoma agent, reduced 
resting pupil size and contraction amplitude of pupillary light reflex 
in healthy adults (12). Dorzolamide, a carbonic anhydrase inhibitor 
used in glaucoma, did not affect the pupillary light reflex (13, 14).
The main purpose of this study was to investigate the short-term 
effect of anti-glaucoma medications on the blue light elicited PIPR 
in healthy individuals.
Materials and Methods
In this randomized, double-masked, crossover trial, the short-term 
effect of the three most frequently used anti-glaucoma eye drops 
(latanoprost 0.005%, timolol 0.5%, and dorzolamide 2%) on the 
pupillary light reflex were investigated by measuring the pupil 
response before and after administration of the eye drops.
subjects
Twenty-six healthy non-smokers aged 18–40  years with best-
corrected visual acuity ≥1.0 were screened during April–July 2014. 
Exclusion criteria were ocular disease, systemic disease, refractive 
error >6 diopters, history of ocular surgery, use of medications, 
caffeine consumption during day of testing, pregnancy, psychiatric 
disease, lack of cooperation, smoking, and ocular abnormalities. 
Ophthalmologic examinations were performed to ensure normal 
conditions: Snellen visual acuity, Ishihara color vision, swinging 
flash light test, slit lamp examination, and intraocular pres-
sure (IOP) measurement by Goldmann and Icare tonometer 
(Icare TA01i, Icare Finland Oy, Helsinki, Finland). In addition, 
visual field test (Octopus 900, 30°, HAAG-STREIT AG, Koeniz, 
Switzerland), non-mydratic fundus photography (Mark II Retinal 
Camera TRC-NW7SF, Topcon Corporation, Tokyo, Japan), and 
optical coherence tomography (OCT) scanning of the macula 
and optic nerve head (Spectralis OCT, Heidelberg Engineering 
GmbH, Heidelberg, Germany) were conducted. Arterial blood 
pressure, pulse, iris color, height, and weight were recorded. Six 
individuals did not meet the inclusion criteria. Young participants 
were included to create a homogenous study population and to 
counter any age-related bias, thus purifying the effect of drugs.
The trial was approved by Danish National Committee on 
Health Research Ethics (project ID: H-2-2014-029). Informed 
consent was obtained according to WMA Declaration of Helsinki’s 
ethical guidelines.
apparatus and experimental Design
Pupillary response was recorded using a binocular multi-chro-
matic pupillometer (DP-2000 Human Laboratory Pupillometer, 
NeurOptics, Inc., CA, USA). This pupillometer consists of two 
separate integrated stimulation and recording units allowing for 
unilateral or bilateral eye stimulation while recording both the 
direct and the consensual pupillary response simultaneously. An 
adaptive eye cup prevents light scattering. The device is connected 
to a computer laptop with control software program.
The participants were assigned randomly to a sequence of 
latanoprost, timolol, and dorzolamide using a computer-generated 
randomization list including a fourth control test date without 
medication. Drugs were administered in a double masked fashion 
and washout period was minimum 1 week. In each experiment, 
pupil measurements were performed before (baseline), 30 and 
180 min after drug application. Intraocular pressure was measured 
before and 3.5 h after medication. Measurements during the con-
trol visit were performed at equivalent hours. All experiments were 
conducted between 8 a.m. and 2 p,m. in April and September 2014 
to avoid possible circadian and seasonal variations, respectively. 
The study eye for all participants was right eye.
Prior to pupillometry, subjects were adapted to dark for 5 min. 
For each measurement, the pupil size was recorded for 10 s prior 
to light onset, 20 s during the light stimulation, and 60 s after the 
stimulus offset (Figure 1). First, participants were exposed to red 
light (633 nm, 2 log (lux), measured as 300 CD/m2) and 5 min 
later to blue light (463 nm, 2 log (lux), measured as 332 CD/m2). 
The binocular camera tracks and measures both pupils continu-
ously with a frequency of 30 Hz. For both eyes, pupil diameters 
(millimeters), recording time (seconds), and luminance (lux) were 
recorded.
Data Processing and Outcomes
Raw data were imported into the R-statistical package (version 
3.1.0). An algorithm was used to detect and correct artifacts gener-
ated by eyelid blinks. If it was not possible to remove blinks by the 
algorithm, correction was performed manually.
The pupil diameter was normalized, i.e., expressed as the ratio 
relative to the baseline pupil size, and a total of three parameters 
were calculated to describe the pupillary response (15):
 (1) The late post-illumination pupil response (PIPR10–30s), indica-
tive of melanopsin photo pigment activation, was defined 
as the mean pupil constriction from 10 to 30  s after light 
termination (16).
 (2) The early PIPR0–10s, a measure of mixed cone and melanopsin 
response, was defined as the mean pupil response from 0 to 
10 seconds after light termination (16).
 (3) Maximal contraction amplitude (CAmax), a measure of cone 
response, was the maximum pupil constriction during 4 and 
6 s of stimulation period (16).
Primary outcome was the PIPR10–30s to blue light. Secondary 
outcomes, likewise for blue light, were the dark-adapted pupil size 
FigUre 1 | an example of the pupillary light reflex to blue light (463 nm, 
100 lux) and outcomes of this study. The pupillary response is expressed as 
normalized. Time is in seconds (s). PS = mean of absolute pupillary diameter 
during the initial 10 s prior to light onset, CAmax = maximal contraction amplitude 
during 4–6 s of illumination time, PIPR0–10s = mean of early post-illumination 
pupillary response 0–10 s after light offset and PIPR10–30s = mean of late 
post-illumination pupillary response over a period of 10–30 s after light 
termination.
TaBle 1 | late post-illumination pupillary response (PiPr10–30s) to red and blue light measured at baseline and after (30 and 180 min) topical anti-
glaucoma administration.
Mean ± sD p-Value
Baseline 30 min 180 min Baseline vs. after
red light
Dorzolamide 0.052 ± 0.02a 0.053 ± 0.02 0.049 ± 0.02 0.626
Latanoprost 0.048 ± 0.01 0.047 ± 0.02 0.044 ± 0.01 0.334
Timolol 0.045 ± 0.01 0.047 ± 0.03 0.047 ± 0.01 0.836
Control 0.041 ± 0.02 0.044 ± 0.02 0.049 ± 0.01 0.144
p-Value 0.021 0.327 0.664
Blue light
Dorzolamide 0.153 ± 0.07 0.144 ± 0.07 0.145 ± 0.06 0.662
Latanoprost 0.156 ± 0.07 0.146 ± 0.06 0.139 ± 0.06 0.347
Timolol 0.156 ± 0.06 0.149 ± 0.06 0.139 ± 0.07 0.290
Control 0.158 ± 0.07 0.147 ± 0.06 0.147 ± 0.07 0.516
p-Value 0.980 0.986 0.932
Control refers to a visit, where no drugs were applied. 
Results are presented as mean ± SD. p-Value < 0.05 indicates an overall significant change.  
aSignificant difference between the specific drug and control measurement.
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before light onset (PS), maximal contraction amplitude (CAmax), 
and PIPR0–10s (see Figure 1). For all the outcomes, the pupillary 
response to red light was also measured.
statistical analysis
SAS 9.3 and R-statistical package (3.1.0) were used to perform 
statistical analysis and graphics. Data were summarized as mean 
and SD for continuous variables, assuming normally distributed. 
The pupillary response was analyzed in relation to timing (before 
vs. after medication) and drug type with separate one-way analysis 
and the paired observations were accounted by a random statement 
(random coefficient model) of the mixed model procedure. The 
overall comparisons between drugs and control were performed 
with the procedure described above, followed by post hoc tests for 
pairwise comparison of the drugs and control; a Tukey statement 
was used to adjust for multiple comparisons.
results
subject
Final study population consisted of 20 subjects, 8 female and 12 
male with mean age 25 ± 5.39 years. All subjects had normal visual 
field, color vision, and IOP (13 ± 2.24 mmHg). Mean body mass 
index was 24 ± 3.59 kg/m2 and iris color distribution was as the 
following: brown (55%), blue (35%), and green (10%).
Outcome
In the following, for each outcome, baseline examination refers 
to pupillary measurements before medication at the start of each 
examination day, effect of drug over time is the comparison of pupil-
lary response at baseline vs. after medication (30 and 180 min), and 
comparison between drugs and control is the testing of the results for 
drugs against control measurements at 30 and 180 min (Tables 1–4).
TaBle 2 | early post-illumination pupillary response (PiPr0–10s) to red and blue light measured at baseline and after (30 and 180 min) topical anti-
glaucoma administrations.
Mean ± sD p-Value
Baseline 30 min 180 min Baseline vs. after
red light
Dorzolamide 0.175 ± 0.04 0.190 ± 0.04 0.184 ± 0.04 0.069
Latanoprost 0.178 ± 0.04 0.182 ± 0.04 0.173 ± 0.03 0.340
Timolol 0.172 ± 0.04 0.185 ± 0.05 0.181 ± 0.05 0.182
Control 0.180 ± 0.04 0.196 ± 0.04a 0.189 ± 0.03 0.023
p-Value 0.507 0.299 0.157
Blue light
Dorzolamide 0.307 ± 0.06 0.307 ± 0.06 0.307 ± 0.05 0.999
Latanoprost 0.305 ± 0.06 0.300 ± 0.06 0.294 ± 0.05 0.534
Timolol 0.312 ± 0.05 0.313 ± 0.06 0.306 ± 0.05 0.692
Control 0.323 ± 0.05 0.320 ± 0.06 0.319 ± 0.06 0.878
p-Value 0.242 0.203 0.205
Control refers to a visit, where no drugs were applied. 
Results are presented as mean ± SD. p-Value <0.05 indicates the overall significant change. 
aSignificant difference in PIPR0–10s measured at baseline and after (30 and/or 180 min) medication.
TaBle 3 | Pupil size (Ps) in millimeter at baseline and after (30 and 180 min) application with dorzolamide, latanoprost, and timolol.
Mean (mm) ± sD p-Value
Baseline 30 min 180 min Baseline vs. after
Prior to light
Dorzolamide 7.91 ± 0.72 7.82 ± 0.74 7.66 ± 0.71b 0.0004
Latanoprost 7.87 ± 0.65 7.87 ± 0.66 7.89 ± 0.65a 0.808
Timolol 7.92 ± 0.70 7.83 ± 0.76 7.79 ± 0.68b 0.026
Control 7.83 ± 0.70 7.78 ± 0.70 7.76 ± 0.71 0.138
p-Value 0.104 0.247 <0.0001
Control refers to a visit, where no drugs were applied. 
Results are presented as mean ± SD. p-Value < 0.05 indicates the overall significant change. 
aSignificant difference between the specific drug and control measurement.
bSignificant difference between measurement at baseline and after medication.
TaBle 4 | Maximal contraction amplitude (camax) to red and blue light measured before (baseline) and after (30 and 180 min) topical anti-glaucoma 
administration.
Mean ± sD p-Value
Baseline 30 min 180 min Baseline vs. after
red light
Dorzolamide 0.523 ± 0.06 0.525 ± 0.06 0.527 ± 0.06 0.412
Latanoprost 0.534 ± 0.07 0.528 ± 0.06 0.520 ± 0.06 0.193
Timolol 0.522 ± 0.07 0.518 ± 0.06 0.501 ± 0.06a,b 0.016
Control 0.520 ± 0.08 0.530 ± 0.06 0.535 ± 0.05 0.097
p-Value 0.354 0.413 0.001
Blue light
Dorzolamide 0.622 ± 0.03 0.632 ± 0.03 0.632 ± 0.03 0.082
Latanoprost 0.628 ± 0.03 0.628 ± 0.03 0.626 ± 0.02 0.949
Timolol 0.631 ± 0.03 0.632 ± 0.02 0.625 ± 0.02a 0.121
Control 0.633 ± 0.03 0.636 ± 0.03 0.636 ± 0.02 0.615
p-Value 0.236 0.295 0.046
Control refers to a visit, where no drugs were applied. 
Results are presented as mean ± SD. p-Value < 0.05 indicates the overall significant change. 
aSignificant difference between the specific drug and control measurement.
bSignificant difference between measurement at baseline and after medication.
April 2015 | Volume 6 | Article 934
Ba-Ali et al. Anti-glaucoma medications and pupillary light reflex
Frontiers in Neurology | www.frontiersin.org
FigUre 2 | late post-illumination pupillary response (PiPr10–30s) to blue light and the effect of timolol, dorzolamide, and latanoprost. Control refers 
to measurements without medication. PIPR10–30s is presented as mean values ± SD. Time is given as baseline (base.) and after (30 and 180 min) drug 
application.
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late PiPr
Baseline examination
The late PIPR10–30  s to blue light was similar during the days of 
examination (p =  0.980, Table  1; Figure  2). For red light, the 
response was significantly  different (p = 0.021, Table 1). Post hoc 
analysis showed that the difference only applied to the day of 
dorzolamide application (p = 0.003).
Effect of Drug over Time
comparing baseline PIPR10–30s to measurements after medication, 
none of the drugs changed PIPR10–30s to blue or red light signifi-
cantly (p > 0.1 for all data, Table 1).
Comparison Between Drugs and Control
No significant differences were found when comparing PIPR10–30s 
measured during the days the participants received drugs and the 
control day (p > 0.1, Table 1).
early PiPr
Baseline Examination
The post-illumination pupillary constriction 0–10  s after light 
offset (PIPR0–10s) was similar in all examination days, both for red 
and blue light stimulation (red p = 0.507, blue p = 0.242, Table 2).
Effect of Drug over Time
The early PIPR0–10s to both red and blue light was not significantly 
different between baseline and after topical instillation with timo-
lol, dorzolamide, or latanoprost (p >  0.1 for all data, Table 2). 
We did see a significant increase in PIPR0–10s during the control 
day after red light stimulation (p = 0.023), but not after blue light 
(p =  0.878). Post  hoc analysis showed that the difference after 
red light was significant between baseline and 30 min, but not at 
180 min (Table 2).
Comparison Between Drugs and Control
No significant differences were seen for either blue or red 
light comparing the PIPR0–10s after drug applications against 
control measurements (Table 2).
Pupil size
Baseline Examination
Pupil size (PS), measured prior to light onset, did not vary sig-
nificantly at the start of each examination day, i.e., before drug 
administration (p = 0.104, Table 3).
Effect of Drug over Time
Dorzolamide and timolol reduced PS significantly (dorzolamide, 
p = 0.0004 and timolol, p = 0.026, Table 3). Latanoprost did not 
change the PS significantly (p = 0.808).
Comparison Between Drugs and Control
The overall comparison showed that PS was significantly different 
at 180  min (p <  0.0001), but not at 30  min. Post  hoc analyses 
identified that pupil size was largest for latanoprost compared to 
control (0.12 mm, p = 0.026); dorzolamide and timolol had not 
significantly different effect compared to control values (Table 3).
To examine any carryover effect from red to blue light, addi-
tional analyses were performed to compare the PS prior to red 
light stimulation to that before blue light, as measured 5  min 
later. For the initial baseline examination, we found a statistically 
significant difference (p =  0.0232), however the difference was 
clinically negligible (0.05 mm, less than 1%). For the measurements 
at 30 and 180 min, the PS was unchanged between before red light 
illumination and prior to blue light (p > 0.05).
Maximal contraction amplitude
Baseline Examination
CAmax to both red and blue light at the start of each examination 
days did not differ significantly (Table 4).
TaBle 5 | intraocular pressure (iOP) measured before and 3.5 h after 
topical anti-glaucoma administration.
Mean ± sD p-Value
Before after
Drugs
Latanoprost 15 ± 2 11 ± 2 <0.01
Timolol 14 ± 2 10 ± 3 <0.01
Dorzolamide 15 ± 2 11 ± 3 <0.01
Control 13 ± 3 14 ± 2 0.3
p-Value 0.02 <0.01
Control refers to a visit, where no drugs were applied.
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Effect of Drug over Time
CAmax to blue light did not change significantly before and after glau-
coma medications, except for red light, where a significant decrease 
was found at 180 min after instillation with timolol (p = 0.016).
Comparison Between Drugs and Control
Both red and blue light were significantly different at 180 min (red 
light p = 0.001, blue light p = 0.046). Post hoc analysis showed that 
the decreased contraction amplitude was due to timolol (Table 4).
effect of covariates on PiPr and camax
For all parameters mentioned above including effect of drugs over 
time and comparisons between drugs and control, the outcomes 
were analyzed after adjustment for baseline PS, age, gender, 
and iris color. For CAmax to blue light, the p-value did not reach 
statistical significance after adjustment for the baseline PS in the 
model thereby the p-value of 0.046 (Table 4) was reduced to 0.086. 
No other conclusions were changed. In addition, we did not find 
changes of the results due to the different randomization schemes 
of the drugs.
intraocular Pressure
Intraocular pressure before and after drug application and for 
control measurements are summarized in Table 5. All three drugs 
reduced IOP significantly (p < 0.01) after 3.5 h, while the IOP 
during control day increased slightly, although not significantly 
(p = 0.3).
Discussion
Previous studies have shown that anti-glaucoma drugs affect the 
iris. The dilator and sphincter muscles of the iris regulate the 
pupillary size. The main objective of this study was to investigate 
whether the topical anti-glaucoma drugs can alter the PIPR to 
blue light in healthy individuals. This issue is important as pupil-
lometry is gaining more ground in the evaluation of glaucoma. The 
approach was to compare the pupillary light response in healthy 
subjects before and after topical administration of timolol, dor-
zolamide, and latanoprost. As an additional control and to assess 
the variations of pupillary responses over a short time period (8 
a.m. to 2 p.m.), we performed pupillometry during a control day, 
where no medication was applied (control).
Our results demonstrate that PIPR to blue light was unaffected 
by dorzolamide, latanoprost, or timolol (Tables 1 and 2) and no 
significant difference in hour-to-hour measurements through the 
control day was observed. The comparisons between drugs and 
control measurements during baseline examinations and after 
medications neither showed significant differences (Tables  1 
and 2).
PIPR to red light was likewise unaffected by anti-glaucoma 
eye drops. There was a significant variation in the PIPR10–30before 
administration of dorzolamide in comparison to control measure-
ment (Table 1). In addition, the PIPR0–10s to red light increased 
through the control day without any medication (Table 2). These 
two statistically significant findings in relation to red light may 
have the following possible explanations. As reported earlier by 
Herbst et al., both the PIPR0–10s and PIPR10–30s to red light show 
low reproducibility (15). Previous studies have shown that PIPR 
to continuous light of both red and blue colors exhibits significant 
variations over 24 h (17, 18). Our measurements were performed 
from 8 a.m. to 2 p.m., and PIPR0–10s to red light for both drugs 
and control increased during the three subsequent measurements 
throughout the daytime. Subjective sleepiness during the first 
measurement at the early morning could be an explanation for 
this increment, such that the test persons become more alert later 
on the day; Münch et al. showed a correlation between increased 
subject sleepiness and smaller PIPR (18), matching our findings, 
despite not recording the subjects’ alertness during the day. Future 
experiments could begin with a trial stimulation to “awaken the 
subject” or could stimulate the pupil later in the day, e.g., com-
mence at 10 a.m.
Since PIPR to blue light depends on the initial pupil size before 
light onset (19), we investigated the effect of anti-glaucoma eye 
drops on the PS. Dorzolamide reduced PS by 2.4% after 3  h 
(0.0004). Plummer et  al. did not show any significant change 
in PS after application with dorzolamide in glaucomatous dogs 
(14). The inconsistency between our and Plummer’s findings 
could be explained by possible species differences in the effects of 
dorzolamide on the iris contractile muscle, in the same way as it 
was observed by Kaddour-Djebbar et al. for prostaglandin receptor 
agonist on the iris muscle (10).
Latanoprost did not change PS at 0.5 or 3 h (Table 3). Previous 
reports were contradictory, e.g., Dinslage et al. showed that latano-
prost reduced PS in glaucomatous human eyes, while Marchini 
et al. did not report any significant change in glaucoma patients 
(11, 20).
Timolol reduced PS significantly 3  hours after medication 
(Table 3). This miotic effect was very small (1.64%), consistent 
with previous human studies, which also demonstrated a slightly 
non-significant decrease or no change of note in PS (21, 22).
The reducing effect of dorzolamide on the PS was also reported 
by Pfeiffer et al., although their results were statistically not sig-
nificant (23).
The miotic effect of dorzolamide and timolol is an interesting 
finding since in case of substantial alteration in the PS, PIPR to 
blue light changed significantly as shown by Nissen et al. (19). For 
the results reported here, all conclusions remained unchanged after 
adjusting for the PS. Thus, dorzolamide and timolol have a slight, 
but clinical unimportant miotic effect.
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The baseline examinations of the PS did not change significantly 
between examination days, indicating that no carryover effect was 
found from the drugs. We also evaluated if the pause of 5 min 
between red and blue light stimuli in our protocol was sufficient for 
the pupils to return to baseline; for the morning examination (i.e., 
baseline), a significant decrease in PS prior to blue light compared 
to PS before red light stimulation was observed. However, the 
difference was only 0.05 mm (<1%) and no differences were found 
for the examination at 30 and 180 min. Thus, 5 min is a sufficient 
time interval between light stimulations.
The PS did not change significantly during control measurements 
at 8 a.m. to 2 p.m. (Table 3), which is consistent with earlier reports 
investigating the PS variation over a short time period (17, 18).
Blue light CAmax during control day was consistent, revealing no 
variations from 8 a.m. to 2 p.m. in contrast to previous findings, 
Table 4 (17, 18). However, in our study, we did all the measure-
ments between 8 a.m. and 2 p.m. to avoid the diurnal effect.
The difference observed between timolol and control in blue 
light CAmax at 180 min could be explained by modulations of CAmax 
over weeks since the time lag between control measurements and 
the examination day, we applied timolol, was minimum 1 week. 
In addition, the difference was not found when the model was 
adjusted for baseline PS.
Timolol reduced red light elicited CAmax by 3.85% after 180 min 
and moreover, there was a significant difference when comparing 
the drug against control (Table 4). Previous study reported similar 
effect of the non-selective beta-blocker pindolol on the contraction 
amplitude (12).
study limitations
One limitation of the present study was that we investigated the 
short-term effect of topical glaucoma medications. Latanoprost 
induces iris hyperpigmentation after continual use for 
approximately 7 months (24). However, while excessive doses of 
latanoprost may cause iritis, long-term trials do not indicate any 
adverse effects on the iris dynamics (25, 26). Dorzolamide has a 
very long terminal plasma elimination half-life (> 120 days), so 
for this drug, there could be a possible risk of drug effect several 
weeks following its instillation. To shed light on this issue, we 
investigated the carryover effect for the different drugs and found 
no significant change compared to baseline values. The long-term 
(1-year) adverse effects of timolol were studied very carefully by 
Sherwood et al. in a prospective trial – pupillary side effects were 
not reported (27).
Another limitation of the study is the role of preservatives in 
the three drugs. Since benzalkonium chloride (BAC) is added 
as preservative in all the three drugs, any possible effect of this 
preservative on the pupillary light reflex would not be identified 
in this short-term study. Benzalkonium chloride is shown to 
be a cytotoxic substance and cause apoptosis in conjunctival, 
corneal, and trabecular meshwork tissues (28–30). Although the 
penetration of BAC into the rabbit iris after topical instillation 
has been shown, its cytotoxic damage on the iris tissue has not 
been reported yet (31). To our knowledge, the adverse effect of 
the BAC on the iris has neither been investigated in pupillometry 
yet.
The age difference of our study population was 18–40 years, 
thus not representative of the common elderly glaucoma patients. 
Certain changes, possibly affecting the pupillary light response, 
occur with age: age-related miosis, photoreceptor degeneration, 
and decreased light transmission of especially blue light to the 
retina (32–34). However, currently three studies have investi-
gated the effect of the age on the blue light elicited PIPR and 
neither of them showed any significant correlation between age 
and PIPR (2, 19, 35). In particular, Herbst et al. did not show 
correlation between age-related decrease in lens transmission 
and blue light elicited PIPR10–30s (35). Moreover, in our younger 
study population, the effect of the drugs on the pupillary response 
was not biased by other possible age-related factors, which are 
not yet known. We do not expect any effect of glaucoma drugs 
on PIPR10–30s in elderly individuals, such as glaucoma patients. 
However, our findings in a small number of young adults will 
need to be reproduced in a larger group of patients of older age, 
more typical of glaucoma patients, before the study can be applied 
directly to glaucoma patients.
conclusion
Our results demonstrate that PIPR (both PIPR10–30s and PIPR0–10s) 
to blue light was not affected by anti-glaucoma medications. Red 
light elicited PIPR was not affected by topical glaucoma drugs 
either, however since the early PIPR0–10s to red light increased 
significantly over a time period of 8 a.m. to 2 p.m. without medica-
tion, we suggest that this parameter is inconsistent and the results 
should be interpreted with caution. Dorzolamide decreased the 
dark-adapted PS, while timolol reduced both PS and CAmax for 
red light, but neither of these effects was of clinical importance.
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